- 1 Nanopore Metagenomic Sequencing for Detection and Characterization of SARS-CoV-2 in Clinical
- 2 Samples

- 4 Nick P.G. Gauthier¹, Cassidy Nelson², Michael B. Bonsall², Kerstin Locher^{3,4}, Marthe Charles^{3,4},
- 5 Clayton MacDonald^{3,4}, Mel Krajden^{4,5}, Samuel D. Chorlton^{4,6*}, Amee R. Manges^{5,7*}
- 6 ¹Department of Microbiology and Immunology, University of British Columbia, Vancouver, British
- 7 Columbia, Canada
- ²Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford, United
- 9 Kingdom
- 10 ³Division of Medical Microbiology, Vancouver General Hospital, Vancouver, British Columbia, Canada
- ⁴Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British
- 12 Columbia, Canada
- 13 ⁵British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
- 14 ⁶BugSeq Bioinformatics Inc, Vancouver, British Columbia, Canada
- 15 ⁷School of Population and Public Health, University of British Columbia, Vancouver, British Columbia,
- 16 Canada

17

22

- ***Denotes equal contribution**
- 19 Corresponding authors:
- 20 Samuel D. Chorlton, MD, sam@bugseq.com
- 21 Amee R. Manges, MPH, PhD, amee.manges@ubc.ca
- 23 Running Title: Nanopore Metagenomic Sequencing of SARS-CoV-2
- 25 Key words: Nanopore, Metagenomic, SARS-CoV-2, Coronavirus, Molecular epidemiology, Diagnostic,
- 26 Sequence-independent single-primer amplification, NGS

Abstract

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

The COVID-19 pandemic has underscored the need for rapid novel diagnostic strategies to detect and characterize pathogens from clinical specimens. The MinION sequencing device allows for rapid, costeffective, high-throughput sequencing; useful features for translation to clinical laboratory settings. Metagenomic Next-Generation Sequencing (mNGS) approaches provide the opportunity to examine the entire genomic material of a sample; allowing for detection of emerging and clinically relevant pathogens that may be missed in targeted assays. Here we present a pilot study on the performance of Sequence-Independent Single Primer Amplification (SISPA) to amplify RNA randomly for the detection and characterization of SARS-CoV-2. We designed a classifier that corrects for barcode crosstalk between specimens. Our assay yielded 100% specificity overall and 95.2% sensitivity for specimens with a RTqPCR cycle threshold value less than 30. We assembled 10 complete (>95% coverage at 20x depth), and one near-complete (>80% coverage at 20x depth) genomes from 20 specimens that were classified as positive by mNGS. We characterized these genomes through phylogenetic analysis and found that 10/11 specimens from British Columbia had a closest relative to another British Columbian specimen. Of five samples that we had both assembled genomes, as well as Variant of Concern (VOC) PCR results, we found 100% concordance between these results. Additionally, our assay was able to distinguish between the Alpha and Gamma variants, which was not possible with our VOC PCR technique. This study supports future work examining the broader feasibility of SISPA as a diagnostic strategy for the detection and characterization of viral pathogens.

Introduction

The global COVID-19 pandemic and ensuing public health emergency has underscored the need for rapid, comprehensive, and cost-effective viral testing strategies to respond effectively to outbreaks and implement public health policy. COVID-19 disease is caused by severe acute respiratory syndrome

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

coronavirus 2 (SARS-CoV-2); a positive-sense RNA virus from the family *Coronaviridae* (1,2). The current standard for the diagnosis of many viral infections, including SARS-CoV-2, is based on real-time qualitative reverse transcription polymerase chain reaction (RT-PCR) assays (3). Due to its low cost, reliability, and ability to diagnose infection known pathogens, RT-PCR has been at the forefront of viral diagnostics before and during the COVID-19 pandemic (4). However, this method still requires many hours of hands-on time by skilled laboratory technicians and is limited in that it only detects a predetermined number of pathogens that its primers are designed to identify; unknown or unexpected infectious agents will be missed (5). This is a strong rationale for exploring alternative diagnostic strategies that can detect known and novel pathogens. Metagenomic next generation sequencing (mNGS) allows all genetic material recovered directly from a sample to be sequenced and analyzed in a culture-free manner. Sequence-independent single primer amplification (SISPA) (6) is one such mNGS approach. SISPA enables non-selective reverse transcription of all extracted RNA in a sample into cDNA and amplifies the reverse transcribed cDNA using random nonamers tagged to a known primer sequence. This method has been successfully used to detect and assemble genomes of avian RNA viruses (7), canine distemper virus (8), human enterovirus (9), chikungunya virus, Ebola virus, hepatitis C virus (10), influenza virus (11), as well as SARS-CoV-2 for a small number of samples (12,13). Therefore, there is a strong justification for using this approach to enable detection of pathogenic agents in diagnostic laboratories. SISPA and mNGS have several clear advantages over targeted molecular approaches. mNGS enables detection of multiple pathogens and co-infection in a clinical sample, as well as potentially providing information on antimicrobial resistance, virulence, and microbiota-associated dysbiosis at a particular body site (14,15). Despite the potential advantages of this approach for clinical applications, mNGS techniques have not yet been widely adopted due to their high-cost, time-intensive sample preparation, limited access to sequencing infrastructure and lack of robust, easy-to-use and interpret bioinformatics

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

systems (14). Furthermore, the FDA has provided no specific requirements for validation of mNGS-based diagnostic assays; which has made validation and translation of mNGS tools for detection of microorganisms challenging for routine clinical microbiology laboratories (15). The Oxford Nanopore Technologies' (ONT) MinION sequencing platform provides a method for highthroughput, and cost-effective long-read sequencing in a device that fits in the palm of a hand. Sequencing on the MinION device is also less time-intensive than the Illumina sequencing platform (14,16). The portability and cost-effectiveness of MinION sequencing makes Nanopore mNGS uniquely tailored for clinical applications. Despite these advances in long-read clinical sequencing applications, the field of nanopore clinical metagenomics has been largely unexplored. To date, there are only a few studies that examine the use of nanopore-based metagenomics for clinical applications (10,11,17,18). Bioinformatic analysis is also a considerable barrier to adoption of mNGS for clinical diagnostics. The majority of available tools require command line knowledge, significant computing infrastructure, and experience translating bioinformatic results into actionable results (15,19). As well, traditional short read analysis services, such as One Codex and IDseq, were not designed or evaluated with third-generation data (20,21). Several tools have been developed recently to facilitate analysis specifically of nanopore mNGS data, including BugSeq and EPI2ME (22, https://epi2me.nanoporetech.com). BugSeq is a bioinformatics solution designed for clinical microbiology labs, enabling the end-to-end analysis of nanopore sequencing data with a graphical user interface and cloud-based data processing. Its analytical method has been shown to have superior sensitivity and specificity compared to EPI2ME (22), and will be the primary analysis pipeline used in this study. In this pilot study, we examine the feasibility and performance of a SISPA-based Nanopore mNGS assay to detect and characterize SARS-CoV-2 from two distinct study populations using the MinION sequencing device.

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

Materials & Methods *Study population and specimen collection:* Clinical specimens were collected from two different populations. First, oropharyngeal swabs were collected in 2 mL of a guanidinium-based inactivation agent (Prestige Diagnostics) as part of a study conducted to estimate SARS-CoV-2 infection prevalence in a UK community from April to June 2020. Swab samples from 2714 individuals from around the greater Oxford area were collected to compare PCR, serology, and Nanopore sequencing for SARS-CoV-2 infected versus uninfected subjects. A set of eight SARS-CoV-2 PCR positives or indeterminate samples from this population were included in the current study. Second, nasopharyngeal swab specimens collected in 3 mL viral transport medium (Yocon Bio-technology Co. Ltd) were obtained from routine SARS-CoV-2 community testing at Vancouver General Hospital (VGH) or the BC Centre for Disease Control (BCCDC) (Vancouver, British Columbia, Canada) (n = 35). RT-PCR testing for COVID-19 was performed for all samples at either the BCCDC Public Health Laboratory or the medical microbiology laboratory at VGH using either the Roche MagNA Pure extraction system (Roche Diagnostics, Laval, Canada) in combination with detection of E-gene and RdRp gene targets, or the Panther Fusion SARS-CoV-2 assay (Hologic Inc., San Diego, CA) detecting two targets in ORF1ab. Primers for the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) were developed in-house by the BCCDC Public health laboratory and primers for the E gene were based on the World Health Organization RT-qPCR protocol (3). The human RNaseP gene was used as an internal control as suggested by the World Health Organization (https://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR SwineH1Assay-2009 20090430.pdf?ua=1). A table containing primers and probes used for these assays can be found in Supplementary Table 1. Additionally, PCR screening for potential variants of concern (VOCs) (Ex. Alpha, Beta, Gamma, Delta variants) was performed on 11 of the positive swabs obtained from VGH that were collected during May 2021. Primers and probes were designed to target the N501Y and E484K mutations (Supplementary Table 2). Swabs were stored at either -80°C for the oropharyngeal swabs or -

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

20°C for the nasopharyngeal swabs. Specimens were chosen to obtain test performance metrics for Nanopore mNGS across a range of C_t values (Supplementary Figure 1). RNA Extractions: Prior to extraction, samples were vortexed and 200 uL of each sample was centrifuged at 16,000g for 3 minutes to pellet host cells. 140 uL of supernatant was aspirated and viral RNA was extracted from the supernatant using the QIAmp Viral RNA kit (Qiagen) as previously described (11), and eluted in 30 uL nuclease-free water. Samples were treated with TURBO DNase (Thermo Fisher Scientific) and incubated at 37°C for 30 minutes, followed by concentration and clean-up with the RNA Clean & Concentrator-5 kit (Zymo Research); finally, eluting in 8 uL nuclease-free water. SISPA Amplification: SISPA amplification was performed as described previously (9-13). Briefly, concentrated RNA was incubated with primer A (100pmol/uL; 5' - GTTTCCCACTGGAGGATA(N₉) - 3') and then reverse transcribed using SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific). Second strand synthesis was performed using Sequenase Version 2.0 (Thermo Fisher Scientific), following which, RNase H was performed to digest any remaining RNA. Random amplification was performed on each using AccuTaq LA DNA polymerase (Thermo Fisher Scientific) and SISPA primer B (5' -GTTTCCCACTGGAGGATA - 3'). This reaction underwent PCR using the following conditions: initial denaturation for 30 seconds at 98°C, followed by 30 cycles of 94°C for 15 seconds, 50°C for 20 seconds, and 68°C for 2 minutes. A final elongation step of 68°C for 10 minutes was added, prior to a final hold at 4°C. Amplified cDNA was purified using a 1:1 ratio of PCR Clean DX beads (Aline Biosciences) and eluted in 50 uL nuclease-free water. Amplified cDNA was quantified using a Qubit 4 Fluorometer (Thermo Fisher Scientific) and fragment lengths were assessed using the TapeStation 2200 automated electrophoresis platform (Agilent).

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

Library Preparation and MinION Sequencing: Library preparation was performed using ONT's ligation sequencing kit (SQK-LSK109 or SQK-LSK110). Multiplexing was performed using the native barcoding expansion 96 kit (EXP-NBD196). Library preparation was performed according to the manufacturer's instructions, with several key modifications. DNA repair and end-prep was performed with 1000 fmol of input cDNA and the incubation times were increased to 30 minutes at 20°C, followed by 30 minutes at 65°C. For the barcoding reaction 200 fmol of input cDNA was incubated with the native barcodes and Blunt/TA Ligase Master Mix (New England Biolabs) for 20 minutes at room temperature (15-25°C), followed by 10 minutes at 65°C to improve barcode ligation efficiency with smaller fragments. Up to four clinical samples (90 fmol/sample) were multiplexed on each minION flowcell, with the addition of a blank viral transport medium negative control sample to each pooled library. Samples were sequenced on FLO-MIN106 flowcells on MinION MK1b sequencing devices for 72 hours using MinKNOW (Version 4.2.8, Oxford Nanopore Technologies) with live basecalling disabled. Sequence Data Analysis: Raw fast5 files were basecalled using Guppy (Version 5.0.7, Oxford Nanopore Technologies) using the -device cuda:0 flag to enable GPU basecalling. Output fastq files were uploaded to BugSeq (version 1.1, database version: RefSeq on Jan 28, 2021) for metagenomic classification (22), and results classification results were visualized in Recentrifuge (23). A representative html file containing an example visualization output can be found in the supplemental material (Supplementary Data). In brief, reads were demultiplexed with quat using default run parameters (enforcing barcodes on both ends, which we have defined as stringent demultiplexing), followed by quality control with prinseq-lite. Reads shorter than 100bp or those deemed low quality (DUST score less than 7) were discarded. Reads were then classified against all of the microbial genomes in RefSeq, as well as the human genome and a library of common contaminants (see 22 for details). Reads classified as SARS-CoV-2 were extracted and used to build a consensus sequence with Medaka. Bases with less than 20X coverage were masked in accordance with

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

public SARS-CoV-2 sequencing guidelines (https://www.aphl.org/programs/preparedness/Crisis-Management/Documents/APHL-SARS-CoV-2-Sequencing.pdf). SARS-CoV-2 lineages were assessed using Pangolin (Version 3.1.5, github.com/cov-lineages/pangolin), and phylogenetic analysis was performed with UShER (24) (Database: GISAID, GenBank, COG-UK and CNCB [2021-07-11]). Phylogenetic trees were constructed using augur (25), rooted at the SARS-CoV-2 reference sequence, and visualized in iTOL (26). Antimicrobial resistance genes were detected by aligning reads against the Resfinder database (27) with minimap2, disabling secondary alignments. Analysis from BugSeq outputs and visualizations were performed in RStudio (R version 4.1.0) and Python, with all code available at https://gitlab.com/bugseq/sars-cov-2-nanopore-mngs-performance (28). Ethics Approval: This study obtained research ethics board approval from the University of British Columbia (H20-02152). Approval for collection of participant data was obtained by the Central University Research Ethics Committee at the University of Oxford (R69035). Specimens collected as part of routine testing at VGH and the BCCDC were de-identified and only contained a sample ID number, collection date, C₁, and VOC screening result. Data Availability: Raw FASTQ data has been uploaded to NCBI Bioproject Accession PRJNA752146. Raw reads were mapped against the human reference genome and transcriptome (Ensembl hg38) using minimap2 (2.20) (29) and any human reads were removed. **Results:** Sequence data & Sample Descriptions: Amplified cDNA from a total of 43 patient swabs were sequenced on MinION sequencing devices. Of these samples, 38 were either positive or had indeterminate results based on SARS-CoV-2 RT-PCR and 5

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

samples had negative RT-PCR results. The 38 positive and indeterminate samples had a mean C_t value of 27.6 and ranged from 14.7-38.7 (Supplementary Figure 1). Sample collection dates, sample type, total read counts, as well as dual barcode reads, percent human reads, and SARS-CoV-2 reads per million reads sequenced (RPM) are present in Table 1. On average, negative controls exhibited a 29.7-fold decrease in dual barcode reads compared to the average number of dual barcode specimen reads (Mean dual barcode reads = 20,013, O1: 158.5, O3: 17556). SARS-CoV-2 was detected in similar abundance across our six positive control samples (Mean RPM Dual Barcode: $103,521 \pm 21,070$) Sensitivity, Specificity, & Limit of Detection: We evaluated the test performance of our mNGS assay for detecting SARS-CoV-2. A sample was considered positive if one or more reads were assigned to SARS-CoV-2. Across all clinical samples, we detect SARS-CoV-2 with 78.4% (95%CI 62.8%-88.6%) sensitivity and 100% specificity (95%CI 56.6%-100%) (Table 2). Previous literature has demonstrated decreased sensitivity of mNGS assays above C_t 30 for other viruses (11,30). To assess the dependence of the mNGS assay on C_t value, we performed a subgroup analysis on samples above and below SARS-CoV-2 C₁ 30. For samples with SARS-CoV-2 C₁ < 30, sensitivity was 100% (95% CI 84.5%-100%), while for samples with SARS-CoV-2 C_t greater than 30, sensitivity was 50% (95%CI 27.8%-72.0%). We note that two of 11 negative control samples had a single read assigned to SARS-CoV-2. We investigated these reads (further denoted as read one and two) to identify reasons for false positivity. Both reads had the expected barcode on both ends of the read as identified by BLAST. The first read exhibited 100% identity over the 24 nucleotide barcode on both ends, and the second read had 100% and 83% identity over the 24 nucleotide barcode on both ends. We next search these reads against the NCBI nucleotide database using megaBLAST to assess whether a BugSeq classification error occurred. However, both reads had top hits that exclusively matched SARS-CoV-2 with greater than 95% identity over more than 90% of their total length (923 and 1752 bases, respectively). SARS-CoV-2 was detected,

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

despite strict dual barcode demultiplexing and removal reads with improper barcode insertions. Previous studies have identified barcode crosstalk, ranging from 0.2% to 0.3% of total classified reads, on Nanopore MinION flowcell results (31,32). When we examined the total SARS-CoV-2 read counts for a given flowcell on flowcells with false positive negative controls, we saw that one of those flowcells has the highest total SARS-CoV-2 read count of all flowcells in this study, therefore, we would expect higher levels of barcode crosstalk for that flowcell (Supplementary Figure 2). We adjusted for barcode crosstalk by controlling for the total number of dual-barcoded SARS-CoV-2 reads on each flowcell. If we assume 0.2% of reads have incorrect barcodes ligated on both ends, and that these misclassified reads are evenly distributed across all barcodes on the flowcell, we can subtract the estimated number of misclassified reads from each sample. This correction yielded an acceptable threshold for classifying specimens as positive or negative. After adjusting for barcode crosstalk in this manner, we find that seven samples and two negative controls with SARS-CoV-2 reads detected would be re-classified as negative, and all negative controls are therefore classified correctly. The overall sensitivity and specificity on clinical samples after adjusting for barcode crosstalk are estimated to be 59.5% (95%CI 43.5%-73.7%) and 100% (56.6%-100%), respectively. Grouping by C_t value, the sensitivity estimates are 95.2% (95% CI 77.3%-99.2%) and 12.5% (95% CI 3.5%-36.0%%) for samples below and above C_t 30, respectively (Table 3). RT-qPCR/SISPA Correlation, Genome Coverage, & SARS-CoV-2 Phylogeny: We assessed the relationship between SARS-CoV-2 RT-PCR Ct value and SARS-CoV-2 RPM for dual barcode reads, using stringent demultiplexing analysis parameters. SARS-CoV-2 log-RPM showed a strong linear association with RT-qPCR C_t value ($R^2 = 0.71$), with lower C_t values having a higher RPM on average (Figure 1). This relationship did not differ by RT-qPCR gene target (E-gene, ORF1ab, or RdRp) (Supplementary Figure 3). SARS-CoV-2 genome coverage depth showed a similar relationship, with decreasing coverage depth across the entire genome being associated with increasing C_t value

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

(Figure 2, Table 4). We produced logistic regression models to assess the probability of attaining greater than 95% genome coverage at 1X, 20X, or 50X depth of coverage. We found that for every one unit increase in C₁ value, the odds of recovering a 95% complete genome were 0.765 (95% CI: 0.519, 0.961), 0.263 (95% CI: 0.023, 0.666), or 0.263 (95% CI 0.023, 0.666) on average for coverage depths of 1X, 20X, or 50X, respectively (Figure 3). Interestingly, we did not see any difference in the likelihood of obtaining 95% coverage for 20X or 50X, despite slight differences in coverage depth for both of these thresholds (Table 4; Figure 3). SARS-CoV-2 metagenomic reads were used to reconstruct viral genomes. We produced ten complete (greater than 95% unambiguous bases) and one near-complete consensus genome sequence (greater than 80% unambiguous bases) from our 20 SISPA-positive clinical specimens, masking any bases with less than 20X coverage. Two partial viral genomes were constructed with 20-25% unambiguous bases. Pangolin lineage assignment was successful to all complete or near complete genomes; of these five underwent SARS-CoV-2 VOC PCR testing. All five whole or partial viral genomes were classified as SARS-CoV-2 lineages concordant with PCR results (Table 5). We also detected an additional VOC in a sample that did not undergo VOC PCR testing. We also assessed our complete or near-complete genomes in the context of global SARS-CoV-2 transmission by placing them in a phylogenetic tree containing over two million publicly available SARS-CoV-2 genomes. The ten complete genomes could be placed in the global phylogeny with high confidence (only one maximally parsimonious placement), and the near-complete genome could be placed with lower confidence (nine maximally parsimonious placements). For ten of 11 genomes derived from metagenomic data, the nearest neighbor in this tree was a genome derived from the same province of sample collection, British Columbia. Additionally, for 9/11 study genomes, 80% or more of the nearest 50 genomes were derived from British Columbia; for the remaining two study genomes, 90% or more of the nearest 50 genomes were derived from Canada (Figure 4; Supplementary Figure 4). The UK samples did not yield well covered genomes. Subtrees with nearest neighbors for all study samples are available in the supplementary material (Supplementary Figure 4).

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

Universal Microbial Detection & Antimicrobial Resistance: We searched the BugSeq metagenomic output of our clinical specimens for alternative respiratory viruses or viral or bacterial co-infections. We did not identify any other pathogenic viruses or atypical bacteria such as Chlamydia pneumoniae or Mycoplasma pneumoniae. We did identify several members of the normal nasopharyngeal microbiota, which when found in the lower respiratory tract, may cause disease; these included two samples with Moraxella catarrhalis, seven samples with Haemophilus influenzae or Haemophilus parainfluenzae, three samples with Neisseria meningitidis, three samples with Staphylococcus aureus, two samples with Streptococcus pneumoniae and two samples with Klebsiella pneumoniae (Supplementary Table 3). These results are consistent with other metagenomic sequencing results from the nasopharynx (30). We searched our data for genes conferring antimicrobial resistance, and identified 10 genes across 6 samples. We found two beta-lactamases in our dataset: blaTEM-234, a class A beta-lactamase which has undetermined spectrum and derived from Escherichia coli in sample P22, as well as blaOXA-85, which confers resistance to amoxicillin and amoxicillin-clavulanate, that derived from Fusobacterium psuedoperiodonticum (P9). **Discussion:** Here, we present a robust analysis detailing the performance of SISPA coupled with Nanopore mNGS to detect and characterize SARS-CoV-2 from clinical samples. Clinical specimens exhibiting a C₁ < 30 performed well. However, test performance declined in specimens exhibiting a $C_t \ge 30$ from 96.3% sensitivity for samples below C_t 30 to 12.5% for samples above this cycle threshold. We found an exponentially declining relationship between RPM and C_t value, such that the instantaneous change in read performance was fixed as illustrated in the linear relationship between Log(RPM) and C_t value (Figure 1). This finding is consistent with other reports on the use of SISPA and Nanopore mNGS for respiratory infections (11,33). However, our results are not consistent with SISPA and mNGS results from blood and serum viral diagnostics, where C_t value did not drastically impact genome coverage (34).

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

These inconsistent results may have been influenced by sample type, sample preparation and the relative abundance of host nucleic acid in different sample types. Despite limitations in SISPA and Nanopore metagenomic sequencing sensitivity, this approach remains a valuable technique for the detection of pathogens that are novel, unexpected or uncharacterized, and therefore unsuitable for targeted approaches such as RT-qPCR or emerging CRISPR-Cas-based diagnostics, which focus only on known pathogens (35). Unlike these existing diagnostic methods, Nanopore mNGS can theoretically detect any pathogen and co-infections, characterize changes in the sitespecific microbiota, and capture the carriage of critical virulence or antibiotic-resistant organisms or genes, all of which can impact patient outcomes. Our approach identified several organisms in the nasopharyngeal microbiota that may cause disease in the lower respiratory tract, consistent with sequencing results from a recent study (30). We also did not detect any viral or atypical bacterial coinfections (Supplementary Table 3), concordant with previous reports of a low prevalence of respiratory co-infection in COVID-19 positive samples (36-38). In support of this finding, our study regions saw a dramatic reduction in incidence of other respiratory viruses (eg., influenza and RSV) and bacterial pathogens over our collection period, thought to be secondary to public health interventions. We additionally assessed the ability of SISPA-based mNGS to classify and assemble complete or partial SARS-CoV-2 genomes from RT-qPCR positive specimens. This method can perform dual diagnostic and molecular epidemiology functions. Reliably, we were able to assemble near-complete genomes (minimum 20X coverage) up to C_t 25, underscoring the ability of this approach not only to detect emerging pathogens, but also to characterize them without a priori knowledge of a pathogen's genome sequence. This ability contrasts to amplicon-based sequencing methods, which require the viral sequence to develop primers (39). We performed lineage typing on metagenomic-derived SARS-CoV-2 genomes and found perfect concordance with VOC PCR on a small subset of our samples. Moreover, with the complete and partial genomes we were able to distinguish the P.1 variant from the B.1.351 variant, which

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

the PCR assay was unable to do, as both variants contain the E484K and N501Y mutations in their spike genes targeted by the PCR assay. Our reconstructed viral genomes were further validated through phylogenetic analyses, where 10/11 samples that were of British Columbian origin were most closely related to another British Columbia genome sequence. This highlights the potential of mNGS sequencing to be an all-in-one assay which detects and characterizes pathogens of interest in near real-time, providing critical information for clinical care, infection prevention and control and public health interventions. This study examined the methodological feasibility and validity of Nanopore mNGS. We observed false positive SARS-CoV-2 reads in our negative control samples despite meticulous laboratory preparation, including performing nucleic acid extractions in a biological safety cabinet, using freshly aliquoted reagents, decontamination of all surfaces with ethanol and RNaseZap (Thermo Fisher Scientific), and performing pre-amplification steps in a dedicated PCR area. After investigating these reads, we attribute them to barcode crosstalk, in accordance with previous studies (30,31). While BugSeq implements methods to minimize barcode crosstalk from Nanopore sequencing, including requiring barcodes to be present at both ends of each read and removal of reads with barcodes integrated elsewhere, we developed a method to adjust the total read counts on a flowcell for barcode crosstalk. These enhancements improved assay specificity; however, sensitivity is negatively impacted by this read count adjustment. Interestingly, using the estimated 0.2% expected crosstalk between barcodes based on existing reports in the literature, we find far fewer false positive reads in our negative controls than would be expected (1 read found in each versus 3 and 107 reads expected). We do note that native barcoding on the Nanopore platform is not fully optimized, leading to a significant portion of reads with only a single barcode in our sequencing datasets. This results in a decreased sensitivity, when requiring that barcodes be present on both read ends. Future advances in sequencing chemistry may reduce the prevalence of barcode crosstalk while preserving assay sensitivity.

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

In addition to employing automated demultiplexing and minimizing barcode crosstalk for Nanopore mNGS, we validated the BugSeq as a potentially powerful clinical bioinformatics platform and workflow, including quality control, data visualization, taxonomic classification, consensus sequence generation, data aggregation, and results reporting. Although a lack of straight-forward and user-friendly bioinformatics pipelines has long been a deterrent for clinical laboratories implementing NGS and mNGS methods, our use of BugSeq as a rapid and robust bioinformatics tool has demonstrated the utility of userfriendly platforms for clinical diagnostics and public health service. Indeed, other groups adopting MinION sequencers in clinical microbiology laboratories have reached similar conclusions (40,41). Our pilot study has several limitations. Despite the MinION sequencing device providing high-throughput sequencing data in real-time, this protocol is still significantly more time intensive than RT-PCR as a diagnostic method, requiring a minimum of 12 hours from sample collection to prepared library, and another 72 hours of sequencing to reach maximal pathogen detection sensitivity (although results could be available in as little as 1-2 hours for high viral load samples). The use of liquid handling robots for automated sample extraction, nucleic acid amplification, and library preparation may aid in standardization. Additionally, examining the feasibility of a less time intensive library preparation protocol such as the Rapid Barcoding Kit (Oxford Nanopore Technologies) for this approach will aid in the optimization and translation of Nanopore mNGS for routine clinical use. The SISPA approach is also limited in that it performs random amplification of both host and microbial nucleic acids. The high percentage of host RNA in nasopharyngeal/oropharyngeal swabs limits our ability to rapidly detect viruses with comparable sensitivity to PCR, requiring deeper sequencing than what is currently feasible on a MinION. Therefore, this sequencing strategy may not be optimal for samples expected to have very few viral or bacterial nucleic acids where sensitivity is paramount. We note that while assay sensitivity has played an important role in public discourse surrounding SARS-CoV-2 testing, there is some data to suggest that lower viral loads cannot be cultured and are less likely to be transmissible (https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf). This issue

is further complicated by the difficulty of employing host nucleic acid removal techniques on lowbiomass samples. Interestingly, the detection of host nucleic acids via mNGS may be useful, as samples with lower host nucleic acid content have been shown to be associated with higher rates of false-negative COVID-19 RT-PCR tests, presumably due to sample quality (42). Regardless, methods to enrich for pathogen sequences or deplete host DNA to increase sensitivity have been examined (43-45), and may prove useful for future clinical metagenomics studies. Our pilot study represents the first analysis of performance and feasibility of SISPA-based Nanopore mNGS for the detection and characterization of SARS-CoV-2. We were able to successfully detect SARS-CoV-2 with 100% specificity and near perfect sensitivity for samples below C_t 30 when adjusting for barcode crossover. We were also able to assemble SARS-CoV-2 genomes and characterize viral lineages reliably in 10/13 of samples below C_t 25. This assay has the ability not only to detect known pathogens and co-infections, but can also detect emerging pathogens, assess microbiota states, and capture resistance and virulence genes. This approach holds promise as a tool for clinical diagnostics and public health surveillance.

416 **References:** 417 1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, 418 Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. 2020. A new 419 coronavirus associated with human respiratory disease in China. Nature 579:265–269. 420 2. Tavares R de CA, Mahadeshwar G, Pyle AM. 2020. The global and local distribution of RNA 421 structure throughout the SARS-CoV-2 genome. J Virol https://doi.org/10.1101/2020.07.06.190660. 422 3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, 423 Schneider J, Luisa Schmidt M, GJC Mulders D, Haagmans BL, van der Veer B, van den Brink S, 424 Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, 425 Koopmans MP, Drosten C, Victor CM, Olfert L, Marco K, Richard M, Adam M, Daniel CK, Tobias 426 B, Sebastian B, Julia S, Marie Luisa S, Daphne GJC M, Bart HL, der Veer Bas V, den Brink Sharon 427 V, Lisa W, Gabriel G, Jean-Louis R, Joanna E, Maria Z, Malik P, Herman G, Chantal R. 2020. 428 Detection of 2019 -nCoV by RT-PCR. Euro Surveill 25:1-8. 429 4. Li X, Geng M, Peng Y, Meng L, Lu S. 2020. Molecular immune pathogenesis and diagnosis of 430 COVID-19. J Pharm Anal 10:102-108. 431 5. Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. 2020. Overcoming the bottleneck 432 to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection. 433 Cold Spring Harb Lab Press 26:771–783. 434 6. Reyes GR, Kim JP. Sequence-independent, single-primer amplification (SISPA) of complex DNA 435 populations. Mol Cell probes 5:473-481. 436 7. Chrzastek K, Lee D hun, Smith D, Sharma P, Suarez DL, Pantin-Jackwood M, Kapczynski DR. 437 2017. Use of Sequence-Independent, Single-Primer-Amplification (SISPA) for rapid detection,

identification, and characterization of avian RNA viruses. Virology 509:159-166.

439 8. Peserico A, Marcacci M, Malatesta D, Di Domenico M, Pratelli A, Mangone I, D'Alterio N, 440 Pizzurro F, Cirone F, Zaccaria G, Cammà C, Lorusso A. 2019. Diagnosis and characterization of 441 canine distemper virus through sequencing by MinION nanopore technology. Sci Rep 9:1–9. 442 9. Wollants E, Maes P, Merino M, Bloemen M, Van Ranst M, Vanmechelen B. 2020. First genomic 443 characterization of a Belgian Enterovirus C104 using sequence-independent Nanopore sequencing. 444 Infect Genet Evol 81:104267. 445 10. Greninger AL, Naccache SN, Federman S, Yu G, Mbala P, Bres V, Stryke D, Bouquet J, Somasekar 446 S, Linnen JM, Dodd R, Mulembakani P, Schneider BS, Muyembe-Tamfum JJ, Stramer SL, Chiu 447 CY. 2015. Rapid metagenomic identification of viral pathogens in clinical samples by real-time 448 nanopore sequencing analysis. Genome Med 7:1–13. 449 11. Lewandowski K, Xu Y, Pullan ST, Lumley SF, Foster D, Sanderson N, Vaughan A, Morgan M, 450 Bright N, Kavanagh J, Vipond R, Carroll M, Marriott AC, Gooch KE, Andersson M, Jeffery K, Peto 451 TEA, Crook DW, Sarah Walker A, Matthews PC. 2020. Metagenomic nanopore sequencing of 452 influenza virus direct from clinical respiratory samples. J Clin Microbiol 58:1-15. 453 12. Moreno GK, Braun KM, Halfmann PJ, Prall TM, Riemersma KK, Haj AK, Lalli J, Florek KR, 454 Kawaoka Y, Friedrich TC, O'Connor DH. 2020. Limited SARS-CoV-2 diversity within hosts and 455 following passage in cell culture. bioRxiv 2020.04.20.051011. 456 13. Moore SC, Penrice-randal R, Alruwaili M, Dong X, Pullan ST, Carter DP, Bewley K, Zhao Q, Sun 457 Y, Hartley C, Zhou E, Solomon T, Beadsworth MBJ, Bogaert D, Crook DW, Matthews DA, 458 Andrew D, Mahmood Z, Aljabr W, Druce J, Vipond RT. 2020. Amplicon based MinION 459 sequencing of SARS-CoV-2 and metagenomic characterisation of nasopharyngeal swabs from 460 patients with COVID-19. medRxiv 2020.03.05.20032011. 461 14. Petersen LM, Martin IW, Moschetti WE, Kershaw CM, Tsongalis GJ. 2020. Third-Generation 462 Sequencing in the Clinical Laboratory: Exploring the Advantages and Challenges of Nanopore 463 Sequencing. J Clin Microbiol 58:1–10.

464 15. Chiu CY, Miller SA. 2019. Clinical metagenomics. Nat Rev Genet 20:341–355. 465 16. Forbes JD, Knox NC, Peterson C, Reimer AR. 2018. Highlighting Clinical Metagenomics for 466 Enhanced Diagnostic Decision-making: A Step Towards Wider Implementation. Comput Struct 467 Biotechnol J 16:108-120. 468 17. Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S, Turner 469 DJ, Wain J, Leggett RM, Livermore DM, O'Grady J. 2019. Nanopore metagenomics enables rapid 470 clinical diagnosis of bacterial lower respiratory infection. Nat Biotechnol 37:783–792. 471 18. Schmidt K, Mwaigwisya S, Crossman LC, Doumith M, Munroe D, Pires C, M. Khan A, Woodford 472 N, Saunders NJ, Wain J, O'Grady J, Livermore DM. 2017. Identification of bacterial pathogens and 473 antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing. J 474 Antimicrob Chemother 72:104–114. 475 19. Chiang AD, Dekker JP. 2020. From the pipeline to the bedside: Advances and challenges in clinical 476 metagenomics. J Infect Dis 221:S331-S340. 477 20. Minot S, Krumm N, Greenfield N. 2015. One Codex: A Sensitive and Accurate Data Platform for 478 Genomic Microbial Identification. bioRxiv 027607. 479 21. Kalantar KL, Carvalho T, De Bourcy CFA, Dimitrov B, Dingle G, Egger R, Han J, Holmes OB, 480 Juan YF, King R, Kislyuk A, Lin MF, Mariano M, Morse T, Reynoso L V., Cruz DR, Sheu J, Tang 481 J, Wang J, Zhang MA, Zhong E, Ahyong V, Lay S, Chea S, Bohl JA, Manning JE, Tato CM, DeRisi 482 JL. 2021. IDseq-An open source cloud-based pipeline and analysis service for metagenomic 483 pathogen detection and monitoring. Gigascience 9:1-14. 484 22. Fan J, Huang S, Chorlton SD. 2021. BugSeq: a highly accurate cloud platform for long-read 485 metagenomic analyses. BMC Bioinformatics 22:1-12. 486 23. Martí JM. 2019. Recentrifuge: Robust comparative analysis and contamination removal for 487 metagenomics. PLoS Comput Biol 15:1-24.

488	24.	Turakhia Y, Thornlow B, Hinrichs AS, De Maio N, Gozashti L, Lanfear R, Haussler D, Corbett-
489		Detig R. 2021. Ultrafast Sample placement on Existing tRees (UShER) enables real-time
490		phylogenetics for the SARS-CoV-2 pandemic. Nat Genet 53:809–816.
491	25.	Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, Neher
492		RA. 2018. NextStrain: Real-time tracking of pathogen evolution. Bioinformatics 34:4121–4123.
493	26.	Letunic I, Bork P. 2016. Interactive tree of life (iTOL) v3: an online tool for the display and
494		annotation of phylogenetic and other trees. Nucleic Acids Res 44:W242-W245.
495	27.	Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
496		Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK, Stingl
497		K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum MF, Duggett
498		NA, Kempf I, Nykäsenoja S, Olkkola S, Wieczorek K, Amaro A, Clemente L, Mossong J, Losch S,
499		Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for predictions of phenotypes from
500		genotypes. J Antimicrob Chemother 75:3491–3500.
501	28.	RStudio Team (2020). RStudio: Integrated Development for R. RStudio, PBC, Boston, MA URL
502		http://www.rstudio.com/.
503	29.	Li H. 2018. Minimap2: Pairwise alignment for nucleotide sequences. Bioinformatics 34:3094–3100.
504	30.	Xu Y, Lewandowski K, Downs L, Kavanagh J, Hender T, Lumley S, Jeffery K, Foster D, Sanderson
505		N, Vaughan A, Morgan M, Vipond R, Carroll M, Peto T, Crook D, Walker AS, Matthews P, Pullan
506		S. 2021. Nanopore metagenomic sequencing of influenza virus directly from respiratory samples:
507		diagnosis, drug resistance and nosocomial transmission. Eurosurveillance 26:1–12.
508	31.	Xu Y, Lewandowski K, Lumley S, Pullan S, Vipond R, Carroll M, Foster D, Matthews PC, Peto T,
509		Crook D. 2018. Detection of viral pathogens with multiplex nanopore MinION sequencing: Be
510		careful with cross-Talk. Front Microbiol 9:1–7.

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

32. Wick RR, Judd LM, Holt KE. 2018. Deepbinner: Demultiplexing barcoded Oxford Nanopore reads with deep convolutional neural networks. PLoS Comput. Biol.doi.org/10.1371/journal.pcbi.1006583 33. Klaudia Chrzastek, Chandana Tennakoon, Dagmara Bialy, Graham Freimanis JF and HS. 2021. A random priming amplification method for whole genome sequencing of SARS-CoV-2 and H1N1 influenza A virus. bioRxiv 2021.06.25.449750. 34. Kafetzopoulou LE, Efthymiadis K, Lewandowski K, Crook A, Carter D, Osborne J, Aarons E, Hewson R, Hiscox JA, Carroll MW, Vipond R, Pullan ST. 2018. Assessment of metagenomic Nanopore and Illumina sequencing for recovering whole genome sequences of chikungunya and dengue viruses directly from clinical samples. Eurosurveillance 23:1-13. 35. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. 2019. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc 14:2986-3012. 36. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JPR, Daneman N. 2020. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 26:1622–1629. 37. Lansbury L, Lim B, Baskaran V, Lim WS. 2020. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 81:266-275. 38. Karaba SM, Jones G, Helsel T, Smith LL, Avery R, Dzintars K, Salinas AB, Keller SC, Townsend JL, Klein E, Amoah J, Garibaldi BT, Cosgrove SE, Fabre V. 2021. Prevalence of co-infection at the time of hospital admission in COVID-19 Patients, A multicenter study. Open Forum Infect Dis 8:1-7. 39. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, Oliveira G, Robles-Sikisaka R, Rogers TF, Beutler NA, Burton DR, Lewis-Ximenez LL, Jesus JG de, Giovanetti M, Hill S, Black A, Bedford T, Carroll MW, Nunes M, Jr LCA, Sabino EC, Baylis SA, Faria N, Loose M, Simpson JT, Pybus OG, Andersen KG, Loman NJ. 2017. Zika and other virus genomes directly from clinical samples. Nat Protoc 12:1261–1276.

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

40. Chorlton SD, Ritchie G, Lawson T, McLachlan E, Romney MG, Matic N, Lowe CF. 2021. Nextgeneration sequencing for cytomegalovirus antiviral resistance genotyping in a clinical virology laboratory. Antiviral Res 192:105123. 41. Matic N, Lowe CF, Ritchie G, Stefanovic A, Lawson T, Jang W, Young M, Dong W, Brumme ZL, Brumme CJ, Leung V, Romney MG. 2021. Rapid detection of SARS-CoV-2 variants of concern, including B.1.1.28/P.1, British Columbia, Canada. Emerg Infect Dis 27:1673–1676. 42. Kinloch NN, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T, Brad Jones R, Montaner JSG, Leung V, Romney MG, Stefanovic A, Matic N, Lowe CF, Brumme ZL. 2020. Suboptimal biological sampling as a probable cause of false-negative COVID-19 diagnostic test results. J Infect Dis 222:899-902. 43. Deng X, Achari A, Federman S, Yu G, Somasekar S, Bártolo I, Yagi S, Mbala-Kingebeni P, Kapetshi J, Ahuka-Mundeke S, Muyembe-Tamfum JJ, Ahmed AA, Ganesh V, Tamhankar M, Patterson JL, Ndembi N, Mbanya D, Kaptue L, McArthur C, Muñoz-Medina JE, Gonzalez-Bonilla CR, López S, Arias CF, Arevalo S, Miller S, Stone M, Busch M, Hsieh K, Messenger S, Wadford DA, Rodgers M, Cloherty G, Faria NR, Thézé J, Pybus OG, Neto Z, Morais J, Taveira N, R. Hackett J, Chiu CY. 2020. Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance. Nat Microbiol 5:443-454. 44. Yap M, Feehily C, Walsh CJ, Fenelon M, Murphy EF, McAuliffe FM, van Sinderen D, O'Toole PW, O'Sullivan O, Cotter PD. 2020. Evaluation of methods for the reduction of contaminating host reads when performing shotgun metagenomic sequencing of the milk microbiome. Sci Rep 10:1–11. 45. Ji XC, Zhou LF, Li CY, Shi YJ, Wu ML, Zhang Y, Fei XF, Zhao G. 2020. Reduction of Human DNA Contamination in Clinical Cerebrospinal Fluid Specimens Improves the Sensitivity of Metagenomic Next-Generation Sequencing. J Mol Neurosci 70:659-666.

Table 1: Study sample descriptions and sequencing results

Study ID	Collection Location	Swab Type	Collection Date	Ct Value	Gene	Kit	Reads	Dual Barcode	% Human	RPM (Dual Barcode)
P1	VGH	NPS	Fall 2020	37.1	ORF1ab	SQK- LSK109	2,592,365	580,829	90	3,030.15
P2	VGH	NPS	Fall 2020	24.1	ORF1ab	SQK- LSK109	2,196,488	425,936	50	62,401.39
P3	VGH	NPS	Fall 2020	14.7	ORF1ab	SQK- LSK109	1,480,039	268,331	8	889,826.37
P4	Oxford	OPS	Spring 2020	25.4	E-gene	SQK- LSK109	1,681,970	194,567	62	3,135.17
P5	Oxford	OPS	Spring 2020	29.9	E-gene	SQK- LSK109	1,487,346	369,374	81	2.71
P6	Oxford	OPS	Spring 2020	34.1	E-gene	SQK- LSK109	1,484,871	224,739	39	0
P7	Oxford	OPS	Spring 2020	35.4	E-gene	SQK-	1,871,165	315,162	88	0
P8	Oxford	OPS	Spring 2020	38.7	E-gene	LSK109 SQK-	4,892,596	1,648,997	79	0
P9	Oxford	OPS	Spring 2020	31.7	E-gene	SQK-	3,095,244	853,190	54	0
P10	Oxford	OPS	Spring 2020	Indeterminate	E-gene	LSK109 SQK-	3,195,376	1,209,061	65	0
P11	Oxford	OPS	Spring 2020	Indeterminate	E-gene	SQK-	2,642,491	758,333	28	0
P12	BCCDC	NPS	Fall 2020	36.13	E-gene	LSK109 SQK-	1,894,335	425,729	91	2.35
P13	BCCDC	NPS	Fall 2020	35.21	E-gene	LSK110 SQK-	2,612,555	636,570	0.2	0
P14	BCCDC	NPS	Fall 2020	33.33	E-gene	LSK110 SQK-	3,335,378	794,876	16	1.26
P15	BCCDC	NPS	Fall 2020	33.73	E-gene	LSK110 SQK-	3,689,514	897,886	98	0
P16	BCCDC	NPS	Fall 2020	33.63	E-gene	LSK110 SQK-	2,301,355	593,209	80	5.06
P17	BCCDC	NPS	Fall 2020	Indeterminate	NA	LSK110 SQK-	1,412,609	384,971	10	38.96
P18	BCCDC	NPS	Fall 2020	Indeterminate	NA	LSK110 SQK-	1,269,020	256,134	92	0
P19	BCCDC	NPS	Fall 2020	36.33	E-gene	LSK110 SQK-	2,588,988	744,812	82	0
P20	VGH	NPS	Spring 2021	35.6	ORF1ab	LSK110 SQK-	1,535,450	431,421	48	2.32
P21	VGH	NPS	Spring 2021	34.3	ORF1ab	LSK110 SQK-	1,553,510	411,279	37	2.43
P22	VGH	NPS	Spring 2021	33.7	ORF1ab	LSK110 SQK-	1,206,439	328,369	47	3.05
P23	VGH	NPS	Spring 2021	21.4	ORF1ab	LSK110 SQK-	1,584,504	499,025	7	17,462.05
P24	VGH	NPS	May 2021	15.5	ORF1ab	LSK110 SQK-	2,875,078	728,905	84	58,192.77
P25	VGH	NPS	May 2021	16.1	ORF1ab	LSK110 SQK-	2,184,440	484,358	87	68,748.74
P26	VGH	NPS	May 2021	16.1	ORF1ab	LSK110 SQK-	968,712	301,091	49	493,422.25
P27	VGH	NPS	May 2021	17	ORF1ab	LSK110 SQK-	2,550,631	737,603	81	60,411.90
P28	VGH	NPS	May 2021	17.7	ORF1ab	LSK110 SQK-	2,151,872	503,298	87	22,088.31
P29	VGH	NPS	May 2021	20	ORF1ab	LSK110 SQK-	993,047	212,823	77	47,057.88
P30	VGH	NPS	Dec 2020	22	E-gene	LSK110 SQK-	707,288	253,025	81	171,129.34
P31	VGH	NPS	May 2021	22.8	ORF1ab	LSK110 SQK- LSK110	2,009,926	456,803	98	1,136.16
P32	VGH	NPS	May 2021	23.5	ORF1ab	SQK-	3,173,498	687,623	99	373.75
P33	VGH	NPS	May 2021	24.4	ORF1ab	LSK110 SQK-	1,597,376	239,837	85	1,054.88
P34	VGH	NPS	May 2021	25.5	ORF1ab	LSK110 SQK- LSK110	1,103,117	283,010	99	38.87
			May 2021		ORF1ab	SQK-		,		
P35	VGH	NPS NPS	May 2021	27.3		LSK110 SQK-	3,325,162	1,042,089	95	2.88
P36	VGH			27.7	ORF1ab	LSK110 SQK-	1,374,869	322,646	87	27.89
P37	VGH	NPS	July 2020 May 2021	28	E-gene	LSK110	1,365,733	278,532	86	240.55
P38	VGH	NPS	May 2021	30.6	ORF1ab	SQK- LSK110 SQK-	4,458,073	1,335,187	98	49.43
N1	VGH	NPS	May 2021	NA	NA	LSK110 SQK-	1,803,891	521,584	96	0
N2	VGH	NPS	May 2021	NA	NA	LSK110 SQK-	1,932,656	645,041	96	0
N3	VGH	NPS	May 2021	NA	NA	LSK110 SQK-	3,421,518	1,053,199	98	0
N4	VGH	NPS	May 2021	NA	NA	LSK110 SQK-	4,947,322	1,539,940	75	0
N5	VGH	NPS	141ay 2021	NA	NA	LSK110	1,386,059	722,140	90	0

Table 2: Overall sample classification, before adjustment for barcode crosstalk

		Positive by mNGS	Negative by mNGS	Sum
True positive	Ct≤30	21	0	21
	Ct>30	8	8	16
True negative		0	5	5
Sum		29	13	

Table 3: Overall sample classification, after adjustment for barcode crosstalk

		Positive by mNGS	Negative by mNGS	Sum
True positive	Ct≤30	20	1	21
	Ct>30	2	14	16
True negative		0	5	5
Sum		22	20	

Table 4: Percent SARS-CoV-2 genome coverage for samples classified as mNGS SARS-CoV-2 positive

following 0.2% crosstalk correction

		RPM (Dual	50X	20X	1X
Study ID	Ct Value	Barcode)	Coverage	Coverage	Coverage
P1	37.1	3,030.15	26.25	80.09	99.85
P2	24.1	62,401.39	99.85	99.94	100
P3	14.7	889,826.37	99.98	100	100
P4	25.4	3,135.17	1.57	23.71	100
P23	21.4	17,462.05	98.85	99.78	99.95
P24	15.5	58,192.77	99.8	99.91	100
P25	16.1	68,748.74	99.85	99.97	100
P26	16.1	493,422.25	99.99	100	100
P27	17	60,411.90	99.81	99.89	100
P28	17.7	22,088.31	99.78	99.79	100
P29	20	47,057.88	99.59	99.75	100
P30	22	171,129.34	99.8	99.85	100
P31	22.8	1,136.16	0	20.01	99.99
P32	23.5	373.75	0	3.87	98.94
P33	24.4	1,054.88	0	0	98.74
P34	25.5	38.87	0	0	15.25
P35	27.3	2.88	0	0	3.63
P36	27.7	27.89	0	0.3	3.85
P37	28	240.55	0	0.07	47.25
P38	30.6	49.43	0	0	72.79

Table 5: SARS-CoV-2 Variant of Concern PCR and Pangolin classification results

	RPM (Dual		
Study ID	Barcode)	VOC PCR Result	Pangolin Lineage (Scorpio Call)
P1	3,030.15	Not Performed	B.1.2
P2	62,401.39	Not Performed	B.1.128
P3	889,826.37	Not Performed	B.1.2
P4	3,135.17	Not Performed	None
P23	17,462.05	Not Performed	B.1.2
P24	58,192.77	Not Performed	P.1 (Gamma)
		Presumptive Positive Variant of	
		Concern. Spike gene N501Y and	
D25	CO 740 74	E484K mutations DETECTED by NAT.	D.1 (C)
P25	68,748.74		P.1 (Gamma)
		Presumptive Positive B.1.1.7 Variant of	
		Concern. Spike gene N501Y mutation	
P26	493,422.25	DETECTED by NAT. No E484K mutation detected.	D 1 1 7 (Alpha)
F20	493,422.23	Presumptive Positive B.1.1.7 Variant of	B.1.1.7 (Alpha)
		Concern. Spike gene N501Y mutation	
		DETECTED by NAT. No E484K	
P27	60,411.90	mutation detected.	B.1.1.7 (Alpha)
127	00,111.90	Presumptive Positive Variant of	B.I.I. (Tuphu)
		Concern. Spike gene N501Y and	
		E484K mutations DETECTED by	
P28	22,088.31	NAT.	P.1 (Gamma)
120	22,000.01	Presumptive Positive B.1.1.7 Variant of	TT (Guillian)
		Concern. Spike gene N501Y mutation	
		DETECTED by NAT. No E484K	
P29	47,057.88	mutation detected.	B.1.1.7 (Alpha)
P30	171,129.34	Not Performed	B.1.36.36
		Presumptive Positive Variant of	
		Concern. Spike gene N501Y and	
		E484K mutations DETECTED by	
P31	1,136.16	NAT.	None
		Negative. No Spike gene N501Y or	
P32	373.75	E484K mutations detected by NAT.	None
		Presumptive Positive B.1.1.7 Variant of	
		Concern. Spike gene N501Y mutation	
		DETECTED by NAT. No E484K	
P33	1,054.88	mutation detected.	None
		Presumptive Positive Variant of	
		Concern. Spike gene N501Y and	
70.4	20.05	E484K mutations DETECTED by	
P34	38.87	NAT.	None
P35	2.88	Not Performed Programming Positive Variant of	None
		Presumptive Positive Variant of	
		Concern. Spike gene N501Y and	
P36	27.89	E484K mutations DETECTED by NAT.	None
P37	240.55	Not Performed	None
r3/	440.33	Negative. No Spike gene N501Y or	NOTIC
P38	49.43	E484K mutations detected by NAT.	None
1 30	47.43	L-10-1X mutations detected by IVA1.	TONE




Figure 1: Log SARS-CoV-2 reads per million reads sequenced across C_t value (E gene or ORF1ab) for all RT-qPCR positive samples. 95% confidence intervals for the linear regression line are shaded in grey. Coefficient of determination = 0.71.




Figure 2: Coverage depth for samples classified as positive by our classifier with log depth of coverage on the y-axis and SARS-CoV-2 reference genome position on the x-axis




Figure 3: Probability of obtaining greater than 95% genome coverage (1 = Yes, 0 = No) for RT-qPCR positive study samples across C_t value for **a.** 1x, **b.** 20x, and **c.** 50x genome coverage. Logistic regression models are represented in blue.




Figure 4: Study samples (marked as P1, P2, etc.) and their nearest three neighbors from all publicly available SARS-CoV-2 sequences